ReviewAntiviral research2009
Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.
Review in Antiviral research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Mysterious Oropouche virus: Transmission, symptoms, and control.Infectious medicine · 2025Review
- Rift Valley fever: A zoonotic disease with global potential.Open veterinary journal · 2025Review
- Novel replication-competent reporter-expressing Rift Valley fever viruses for molecular studies.Journal of virology · 2025Article
- Bunyaviruses: Expression of Recombinant Glycoproteins from Insect Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Segmented, Negative-Sense RNA Viruses of Humans: Genetic Systems and Experimental Uses of Reporter Strains.Annual review of virology · 2023Review
- Identification of an Arylnaphthalene Lignan Derivative as an Inhibitor against Dengue Virus Serotypes 1 to 4 (DENV-1 to -4) Using a Newly Developed DENV-3 Infectious Clone and Replicon.Microbiology spectrum · 2023Article
- Innate Immunity to Orthohantaviruses: Could Divergent Immune Interactions Explain Host-specific Disease Outcomes?Journal of molecular biology · 2022Review
- Development of Rice Stripe Tenuivirus Minireplicon Reverse Genetics Systems Suitable for Analyses of Viral Replication and Intercellular Movement.Frontiers in microbiology · 2021Article
- Development and Characterization of a Reverse Genetics System for a Human-Derived Severe Fever With Thrombocytopenia Syndrome Virus Isolate From South Korea.Frontiers in microbiology · 2021Article
- Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge.PLoS neglected tropical diseases · 2020Article
- Rift Valley Fever: Important Considerations for Risk Mitigation and Future Outbreaks.Tropical medicine and infectious disease · 2020Review
- Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound.Scientific reports · 2018Article
- Vector competence of Aedes vexans (Meigen), Culex poicilipes (Theobald) and Cx. quinquefasciatus Say from Senegal for West and East African lineages of Rift Valley fever virus.Parasites & vectors · 2016Article
- Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.Journal of virology · 2015Article
- A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2014Article
- Predicting the mosquito species and vertebrate species involved in the theoretical transmission of Rift Valley fever virus in the United States.PLoS neglected tropical diseases · 2014Article
- Statistical modeling of the abundance of vectors of West African Rift Valley fever in Barkédji, Senegal.PloS one · 2014Article
- Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.Virology journal · 2013Article
- Construction and characterisation of a complete reverse genetics system of dengue virus type 3.Memorias do Instituto Oswaldo Cruz · 2013Article
- IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus.Journal of virology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The advent of reverse genetics technology has revolutionized the study of RNA viruses, making it possible to manipulate their genomes and evaluate the effects of these changes on their biology and pathogenesis. The fundamental insights gleaned from reverse genetics-based studies over the last several years provide a new momentum for the development of designed therapies for the control and prevention of these viral pathogens. This review summarizes the successes and stumbling blocks in the development of reverse genetics technologies for Rift Valley fever virus and their application to the further dissection of its pathogenesis and the design of new therapeutics and safe and effective vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.